Adma Biologics, Inc.

Health Care
Biotechnology: Biological Products (No Diagnostic Substances)
www.admabiologics.com

Moat Score

Market Cap $5.41B
PE 27
Debt -
Cash $103.15M
EV -
FCF $110.45M

Earnings

loading chart...

Sales & Net Margins

loading chart...

Earnings	$197.67M
EBIT	$138.98M
ROE	57%
ROA	28%
FCF	$110.45M
Equity	$349.02M
Growth Stability	1
PE	27.34
PB	15.49
P/FCF	48.94
P/S	12.67
Price/Cash	0.02
Net Margins	46%
Gross Margins	51%
Op. Margins	33%
Sales Growth YoY	59%
Sales Growth QoQ	-2%
Sales CAGR	58%
FCF CAGR	0%
Equity CAGR	53%
Earnings Growth YoY	-734%

Earnings Growth QoQ	212%
Sales CAGR 5Y	76%
FCF CAGR 5Y	4%
Equity CAGR 5Y	24%
Earnings CAGR 3Y	71%
Sales CAGR 3Y	71%
FCF CAGR 3Y	66%
Equity CAGR 3Y	36%
Market Cap	$5.41B
Revenue	$426.45M
Assets	$488.68M
Cash	$103.15M
Shares Outstanding	233.08M
Moat Score	98%
Working Capital	275.87M
Current Ratio	5.97
Gross Profit	$219.55M
Shares Growth 3y	8%
Equity Growth QoQ	51%
Equity Growth YoY	158%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...

ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. Its targeted patient populations include immune-compromised individuals who suffer from an underlying immune deficiency disorder or who may be immune-suppressed for medical reasons. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling and packing services.

SEC Filings

Direct access to Adma Biologics, Inc. (ADMA) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

2024
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2023
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2022
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31

Sector Comparison

How does Adma Biologics, Inc. compare to its competitors?

Loading chart...

Peter Lynch's Chart

This chart shows the current pricing of Adma Biologics, Inc. compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

loading chart...

Adma Biologics, Inc. Discounted Cash Flow

Fully customizable DCF calculator online for Adma Biologics, Inc..

Years

Calculation mode

= $1.1B

	0	1	2	3	4	5	6	7	8	9	10	TV
fcf	$110M	$111M	$111M	$111M	$112M	$112M	$112M	$113M	$113M	$113M	$114M	$1.1B
DCF		$101M	$92M	$84M	$76M	$70M	$63M	$58M	$53M	$48M	$44M	$438M
Value	$1.1B

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years	12/2015	12/2016	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	12/2024	TTM
Net Margins	-250%	-183%	-192%	-387%	-165%	-179%	-89%	-43%	-11%	46%	46%
ROA	-	-73%	-36%	-68%	-33%	-31%	-21%	-11%	7%	28%	28%
ROE	-	438%	-108%	-333%	-184%	-86%	-51%	-43%	-21%	57%	57%

Good Net Margins (46.35%)

Net Margins are high enough to offer a good protection on the profits in case of higher costs or higher interests. Furthermore higher margins reduce earnings’ volatility.

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years	12/2015	12/2016	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	12/2024	TTM
Debt over FCF	-	-0.43	-0.07	-0.46	-0.91	-	-	-	-	-	-
Debt over Equity	0	-1.77	0.07	1.52	2.77	-	-	-	-	-	-
Growth Stability	-	-	-	-	-	-	-	-	-	-	1

Neutral Debt/FCF ratio (-)

Net Margins are at a level that is not too high nor too low. They are not a competitive advantage but they are not a competitive disadvantage either.

Neutral Debt/Equity ratio (-)

The company has a balance between equity and debt that is not too good nor too bad.

Good Graham’s Stability (1)

The company has a good stability in its earnings, which is a sign of a good competitive advantage.

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years	12/2015	12/2016	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	12/2024	CAGR 5Y
Revenue YoY growth	-	49%	113%	-25%	73%	44%	92%	90%	68%	65%	76%
Earnings YoY growth	-	9%	124%	50%	-27%	57%	-5%	-8%	-57%	-800%	-
Equity YoY growth	-	-643%	-1K%	-51%	32%	237%	60%	8%	-11%	158%	24%
FCF YoY growth	-	19%	118%	62%	24%	43%	10%	-42%	-105%	3K%	4%